Daily Pharma News - 1 October 2026
Welcome to PharmacoLearn's Daily Pharma News for 1 October 2026 - your concise roundup of the most important pharmaceutical, regulatory and healthcare developments from India and around the world, curated for pharmacy students. Today's stories range from India's drug regulator tightening rules on a popular acidity medicine, to the FDA approving a first-in-class Parkinson's drug and the EMA charting a women's-health medicines roadmap. Read on for the full details and what each development means for future pharmacists.
CDSCO Restricts Vonoprazan 10 mg and 20 mg to Prescription-Only Sale in India
India's Central Drugs Standard Control Organisation (CDSCO) has ruled that vonoprazan, in its 10 mg and 20 mg strengths used for acid-related gastrointestinal conditions, must now be sold only against a doctor's prescription. The move targets the growing habit of prolonged self-medication with the potassium-competitive acid blocker (P-CAB), which is widely prescribed as an alternative to proton pump inhibitors for acidity, gastritis and reflux disorders.
The regulator has flagged nutrient-deficiency risks associated with long-term unsupervised use, a concern familiar from the PPI literature on vitamin B12, magnesium and calcium absorption. For pharmacy students, this is a live case study in pharmacovigilance-driven regulation and prescription-drug scheduling: dispensing vonoprazan now requires a valid prescription, and pharmacists have a front-line role in counselling patients against chronic over-the-counter acid suppressant use.
CDSCO Warns Against Indiscriminate NSAID and Antibiotic Use: Kidney Damage and Antimicrobial Resistance
In a circular dated 21 September, CDSCO cautioned doctors, pharmacists and the public against the indiscriminate use of painkillers (NSAIDs) and antibiotics, linking repeated use to kidney complications and antimicrobial resistance (AMR). The warning underscores a double burden: NSAIDs can cause analgesic nephropathy and acute kidney injury through prostaglandin inhibition, while antibiotic overuse accelerates resistant infections - a major public-health concern in India.
This story connects directly to two pillars of the pharmacy curriculum: drug-induced renal toxicity and antimicrobial stewardship. Community pharmacists in India are often the first healthcare contact for patients seeking painkillers or antibiotics without prescriptions, making this CDSCO advisory a timely reminder of the profession's gatekeeping role. Students should note how regulators pair safety communication with prescriber and dispenser responsibility.
Aurobindo Pharma Faces Rs 4.6 Crore GST Demand Order in Telangana
Telangana's GST appellate authority has confirmed a Rs 4.6 crore demand against Hyderabad-based Aurobindo Pharma for FY 2020-21, covering an alleged excess input tax credit (ITC) claim along with interest and penalty. The company has said it will appeal the order before the GST Appellate Tribunal, continuing a legal process that matters for pharma-industry compliance teams across India.
While a Rs 4.6 crore demand is modest for a company of Aurobindo's scale, the case is instructive for pharmacy management students studying pharmaceutical business administration and taxation. GST disputes around input tax credit are a recurring theme in Indian pharma, where complex supply chains and job-work arrangements make ITC reconciliation a persistent challenge. The stock-market reaction - a decline in the company's share price after the order - also illustrates how regulatory news moves pharma equities.
Livzon Pharma Secures NMPA Approval for 11.25 mg Three-Month Leuprorelin Acetate Microspheres in China
China's National Medical Products Administration (NMPA) has approved Livzon Pharmaceutical's 11.25 mg three-month leuprorelin acetate microspheres for injection, making the company China's only domestic holder of the three-month formulation. Leuprorelin, a gonadotropin-releasing hormone (GnRH) agonist, is a mainstay in the hormonal therapy of prostate cancer and breast cancer, where long-acting depot formulations improve patient compliance by reducing injection frequency.
The approval highlights the global race in long-acting injectable oncology formulations and the strategic value of microsphere drug-delivery technology - a topic covered in pharmaceutics and novel drug delivery systems courses. For Indian pharmacy students, the story is also a reminder of how Chinese manufacturers are advancing domestic alternatives to originator depot products, a dynamic that shapes generic and biosimilar markets worldwide, including India's own formulations industry.
Russia's Health Ministry Updates Adult Depression Care Standard, Removes Five Older Drugs
Russia's Health Ministry has published a new care standard for recurrent depressive disorder in adults, expanding non-drug treatment options - including electropuncture, transcranial magnetic stimulation (TMS) and plasmapheresis - while dropping five older drugs from the recommended list. The revision reflects a shift toward evidence-based depression management and away from legacy agents with unfavourable benefit-risk profiles.
For pharmacology students, this is a real-world illustration of how clinical guidelines evolve: older antidepressants can be retired from standard-of-care lists as evidence accumulates and newer or non-pharmacological modalities gain support. The inclusion of neuromodulation techniques like TMS alongside pharmacotherapy also mirrors global trends in treatment-resistant depression, where pharmacists increasingly collaborate with multidisciplinary teams managing both drug and device-based therapies.
FDA Approves AbbVie's Juvmo (Tavapadon): First Selective D1/D5 Dopamine Agonist for Parkinson's Disease
The US Food and Drug Administration (FDA) has approved AbbVie's Juvmo (tavapadon), the first selective D1/D5 dopamine receptor agonist for Parkinson's disease. The drug can be used alone or in combination with levodopa, with approval supported by the TEMPO clinical trial programme, and a US launch is expected in October 2026. Existing dopamine agonists such as pramipexole and ropinirole target D2/D3 receptors, so a selective D1/D5 agent represents a genuinely novel pharmacological approach.
This approval is landmark material for pharmacology and medicinal chemistry students: D1-receptor signalling has long been recognised as central to motor control, but developing a selective, orally active D1/D5 agonist eluded researchers for decades. Pharmacy students should watch how Juvmo's place in therapy develops - particularly its side-effect profile compared with levodopa and D2/D3 agonists, and whether India's regulators follow with their own review in the coming years.
EMA Plans Women's-Health Medicines Regulatory Roadmap by End of 2026
Following a workshop in Amsterdam on 28-29 September, the European Medicines Agency (EMA) announced it will publish a regulatory roadmap for women's-health medicines by the end of 2026, built around ten actions including better female representation in clinical trials and sex-disaggregated (sex-split) data reporting. The initiative addresses the long-standing under-representation of women in drug trials and the resulting gaps in dosing, safety and efficacy evidence.
This development carries global significance for pharmacy education and research. Regulatory science increasingly demands that clinical evidence reflect the populations who will use the medicine - a principle Indian regulators and CDSCO watch closely as global standards converge. For students interested in clinical research, pharmacovigilance or regulatory affairs, the EMA roadmap signals growing career opportunities in women's-health drug development and gender-responsive pharmacovigilance.
Conclusion
Today's news captures three themes every pharmacy student should track: regulation, innovation and equity. India's CDSCO tightened the screws on both vonoprazan and everyday painkillers and antibiotics, reminding us that rational drug use begins with the pharmacist's counter. Meanwhile, genuine innovation arrived from the FDA's first-in-class Juvmo approval and China's new three-month leuprorelin formulation, showing how drug-delivery science and receptor pharmacology keep pushing therapy forward. Finally, Russia's depression-care update and the EMA's women's-health roadmap reflect a maturing, patient-centred regulatory mindset worldwide. The takeaway for future pharmacists: stay fluent in both the science and the rules - your profession sits exactly where the two meet.
References
- ABP Live - CDSCO tightens rules for acidity medicine; doctor's prescription required https://news.abplive.com/lifestyle/cdsco-tightens-rules-for-acidity-medicine-doctor-s-prescription-required-1869016
- Times Now (via Dailyhunt) - CDSCO flags indiscriminate use of painkillers and antibiotics, warns of kidney risk https://m.dailyhunt.in/news/india/english/timesnow+english-epaper-tnneng/cdsco+flags+indiscriminate+use+of+painkillers+and+antibiotics+warns+of+kidney+risk-newsid-n728420649
- Free Press Journal - Aurobindo Pharma stock declines after adverse order in Rs 460 crore GST demand case in Telangana https://www.freepressjournal.in/amp/business/aurobindo-pharma-stock-declines-14-after-adverse-order-in-460-crore-gst-demand-case-in-telangana
- MiniChart - Livzon Pharmaceutical wins NMPA approval for three-month leuprorelin acetate microspheres 11.25 mg https://www.minichart.com.sg/2026/09/29/livzon-pharmaceutical-wins-nmpa-approval-for-three-month-leuprorelin-acetate-microspheres-11-25mg-becoming-chinas-only-domestic-holder-of-the-three-month-formulation/
- GxP News - Russia's Health Ministry publishes new list of treatments for depression in adults https://gxpnews.net/en/2026/09/russias-health-ministry-publishes-new-list-of-treatments-for-depression-in-adults/
- PharmaJournalist - AbbVie's Juvmo wins FDA approval for Parkinson's disease https://www.pharmajournalist.com/abbvies-juvmo-wins-fda-approval-for-parkinsons-disease/
- Europe Pharma Today - EMA women's health medicines roadmap September 2026 https://europepharmatoday.com/news/ema-womens-health-medicines-roadmap-september-2026